These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22236408)

  • 1. Targeting sphingosine kinase-1 to inhibit melanoma.
    Madhunapantula SV; Hengst J; Gowda R; Fox TE; Yun JK; Robertson GP
    Pigment Cell Melanoma Res; 2012 Mar; 25(2):259-74. PubMed ID: 22236408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma.
    Madhunapantula SV; Sharma A; Gowda R; Robertson GP
    Pigment Cell Melanoma Res; 2013 Nov; 26(6):886-99. PubMed ID: 24034838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth.
    Xue Y; Jiang K; Ou L; Shen M; Yang Y; Lu J; Xu W
    Cell Death Dis; 2022 Jul; 13(7):602. PubMed ID: 35831279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual role of sphingosine kinase-1 in promoting the differentiation of dermal fibroblasts and the dissemination of melanoma cells.
    Albinet V; Bats ML; Huwiler A; Rochaix P; Chevreau C; Ségui B; Levade T; Andrieu-Abadie N
    Oncogene; 2014 Jun; 33(26):3364-73. PubMed ID: 23893239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.
    LeBlanc FR; Liu X; Hengst J; Fox T; Calvert V; Petricoin EF; Yun J; Feith DJ; Loughran TP
    Cancer Biol Ther; 2015; 16(12):1830-40. PubMed ID: 26252351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.
    Li W; Li J; Wang Y; Zhang K; Li N; Tian Z; Ni B; Wang H; Ruan Z
    Oncotarget; 2016 Dec; 7(49):80586-80598. PubMed ID: 27811359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A sphingosine kinase-1 inhibitor, SKI-II, induces growth inhibition and apoptosis in human gastric cancer cells.
    Li PH; Wu JX; Zheng JN; Pei DS
    Asian Pac J Cancer Prev; 2014; 15(23):10381-5. PubMed ID: 25556479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
    Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
    Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.
    Powell JA; Lewis AC; Zhu W; Toubia J; Pitman MR; Wallington-Beddoe CT; Moretti PA; Iarossi D; Samaraweera SE; Cummings N; Ramshaw HS; Thomas D; Wei AH; Lopez AF; D'Andrea RJ; Lewis ID; Pitson SM
    Blood; 2017 Feb; 129(6):771-782. PubMed ID: 27956387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SphK1/S1P Mediates PDGF-Induced Pulmonary Arterial Smooth Muscle Cell Proliferation via miR-21/BMPRII/Id1 Signaling Pathway.
    Li F; Wang J; Zhu Y; Liu L; Feng W; Shi W; Wang Q; Zhang Q; Chai L; Li M
    Cell Physiol Biochem; 2018; 51(1):487-500. PubMed ID: 30453304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro.
    Yao C; Wu S; Li D; Ding H; Wang Z; Yang Y; Yan S; Gu Z
    Mol Oncol; 2012 Aug; 6(4):392-404. PubMed ID: 22583777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells.
    Xu L; Zhang Y; Gao M; Wang G; Fu Y
    Biochem Biophys Res Commun; 2016 Apr; 472(4):662-8. PubMed ID: 26920060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingosine kinase-1 inhibition protects primary rat hepatocytes against bile salt-induced apoptosis.
    Karimian G; Buist-Homan M; Schmidt M; Tietge UJ; de Boer JF; Klappe K; Kok JW; Combettes L; Tordjmann T; Faber KN; Moshage H
    Biochim Biophys Acta; 2013 Dec; 1832(12):1922-9. PubMed ID: 23816565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells.
    Leroux ME; Auzenne E; Evans R; Hail N; Spohn W; Ghosh SC; Farquhar D; McDonnell T; Klostergaard J
    Prostate; 2007 Nov; 67(15):1699-717. PubMed ID: 17879964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sphingosine kinase inhibitor SKI-V suppresses cervical cancer cell growth.
    Zhang Y; Cheng L; Shi X; Song Y; Chen XY; Chen MB; Yao J; Zhang ZQ; Cai S
    Int J Biol Sci; 2022; 18(7):2994-3005. PubMed ID: 35541904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Tumorigenic Effect of Sphingosine Kinase 1 and Its Potential Therapeutic Target.
    Wang X; Sun Y; Peng X; Naqvi SMAS; Yang Y; Zhang J; Chen M; Chen Y; Chen H; Yan H; Wei G; Hong P; Lu Y
    Cancer Control; 2020; 27(1):1073274820976664. PubMed ID: 33317322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo.
    Yang L; Weng W; Sun ZX; Fu XJ; Ma J; Zhuang WF
    Biochem Biophys Res Commun; 2015 May; 460(4):903-8. PubMed ID: 25824043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma.
    Chen MH; Yen CC; Cheng CT; Wu RC; Huang SC; Yu CS; Chung YH; Liu CY; Chang PM; Chao Y; Chen MH; Chen YF; Chiang KC; Yeh TS; Chen TC; Huang CY; Yeh CN
    Oncotarget; 2015 Sep; 6(27):23594-608. PubMed ID: 26090720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sphingosine kinase 1 and tumor].
    Zhang CX; He HW; Shao RG
    Yao Xue Xue Bao; 2013 Jul; 48(7):971-8. PubMed ID: 24133963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.